Valuation
- Market cap
- 7,717,000
- Revenue TTM
- $0
- Net income TTM
- $-13,650,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 11,984
- Avg volume
- 49,416
- Day's range
- $1.30 – $1.42
- Shares out
- 5,179,000
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $10.00
Company profile
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment...
Show more
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- Phone
- 972 9 960 1917
- Website
- https://www.regentis.co.il
- Address
- 60, Medinat Hayehudim, Entrance C Herzlia Pituach, Herzliya, Israel
Latest news
No headlines yet.
